Johnson & Johnson

Johnson & Johnson to Participate in the Leerink Global Biopharma Conference

Retrieved on: 
Monday, February 12, 2024

Johnson & Johnson (NYSE: JNJ) will participate in the Leerink Global Biopharma Conference on Tuesday, March 12th, at the Fontainebleau Miami Beach, FL.

Key Points: 
  • Johnson & Johnson (NYSE: JNJ) will participate in the Leerink Global Biopharma Conference on Tuesday, March 12th, at the Fontainebleau Miami Beach, FL.
  • Joe Wolk, Executive Vice President, Chief Financial Officer will represent the Company in a session scheduled at 1:00 p.m. (Eastern Time).
  • The audio webcast replay will be available approximately 48-hrs after the webcast.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20240212450230/en/

Infinite Reality, the Global Leader in Immersive Experiences, Acquires Spatial Web Pioneer Ethereal Engine

Retrieved on: 
Monday, February 12, 2024

LOS ANGELES, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Infinite Reality (“iR”), a leading global provider of cutting-edge virtual, AI-powered immersive experiences, and Ethereal Engine (“Ethereal”), a creator of end-to-end frameworks for web-first, social immersive experiences, announced today that the companies have completed a share-for-share acquisition valuing Infinite Reality at $2.5 billion and Ethereal Engine at $75 million.

Key Points: 
  • Entire Ethereal Engine Team, Including Top Executives and Innovators, Has Joined Infinite Reality
    LOS ANGELES, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Infinite Reality (“iR”), a leading global provider of cutting-edge virtual, AI-powered immersive experiences, and Ethereal Engine (“Ethereal”), a creator of end-to-end frameworks for web-first, social immersive experiences, announced today that the companies have completed a share-for-share acquisition valuing Infinite Reality at $2.5 billion and Ethereal Engine at $75 million.
  • We welcome Liam, Kyle and the entire Ethereal Engine team to Infinite Reality.”
    Ethereal Engine CEO Liam Broza added, "We are incredibly excited to announce this transaction with Infinite Reality.
  • The combination of our shared collective assets together creates an unparalleled leader in the immersive web experiences space.
  • This spatial web platform powered by Ethereal Engine is a no-code solution enabling creators and brands regardless of technical ability to build immersive web experiences in a fraction of the time at a fraction of the price.

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AMAM, HARP, JNPR, TGAN

Retrieved on: 
Saturday, February 10, 2024

If you are an Ambrx shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Ambrx shareholder, click here to learn more about your rights and options .
  • If you are a Harpoon shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM

Retrieved on: 
Saturday, February 10, 2024

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Ambrx Biopharma, Inc. (NasdaqGS: AMAM) to Johnson & Johnson (NYSE: JNJ).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Ambrx Biopharma, Inc. (NasdaqGS: AMAM) to Johnson & Johnson (NYSE: JNJ).
  • Under the terms of the proposed transaction, shareholders of Ambrx will receive $28.00 in cash for each share of Ambrx that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

Kuehn Law Encourages PGTI, AMAM, JNPR, and GLT Investors to Contact Law Firm

Retrieved on: 
Thursday, February 8, 2024

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.

Key Points: 
  • NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.
  • Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.
  • Under the agreement, shareholders of Ambrx Biopharma, Inc. will be entitled to a payment of $28.00 per share in cash.
  • Concerned shareholders are encouraged to contact Justin Kuehn, Esq., at [email protected] or call (833) 672-0814.

INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger – BBAI, PGTI, AMAM, FGH

Retrieved on: 
Thursday, February 8, 2024

NEW YORK, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.

Key Points: 
  • NEW YORK, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report.
  • FG Group Holdings Inc. (NYSE: FGH ), relating to its proposed sale to FG Financial Group, Inc.
  • Under the terms of the agreement, FGH shareholders will receive one share of FG Financial common stock per share they own.
  • Before you hire a law firm, you should talk to a lawyer and ask:
    Do you recover money for shareholders?

Tris Pharma Appoints Michael Magee as Vice President, Quality & Compliance

Retrieved on: 
Wednesday, February 7, 2024

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced the appointment of Michael Magee as vice president, quality and compliance.

Key Points: 
  • Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on attention deficit hyperactivity disorder (ADHD), pain, addiction and neurological disorders, today announced the appointment of Michael Magee as vice president, quality and compliance.
  • Mr. Magee will lead and further strengthen Tris Pharma’s continued development and management of quality and compliance operations via the current Good Manufacturing Practices (cGMP) Compliance function of the organization.
  • “Michael brings a wealth of knowledge and a deep understanding of the regulatory and quality landscape, which will be instrumental in maintaining our unwavering commitment to developing therapeutics of the highest quality across ADHD, pain, addiction and neurological disorders,” said Nicholas Cappuccino, Ph.D., chief quality officer, senior vice president of quality & compliance at Tris Pharma.
  • “I look forward to collaborating with Michael to further elevate our quality assurance and regulatory compliance practices.”

Johnson & Johnson Celebrates Innovation in Novel Drug Delivery Systems with 2023 Dr. Paul Janssen Award

Retrieved on: 
Wednesday, February 7, 2024

NEW BRUNSWICK, N.J., Feb. 7, 2024 /PRNewswire/ -- Johnson & Johnson today announced Robert Langer, Sc.D., of Massachusetts Institute of Technology (MIT) as the winner of the 2023 Dr. Paul Janssen Award for Biomedical Research. Dr. Langer was honored for his groundbreaking work in designing novel drug delivery systems that can deliver medications continuously, precisely, and at controlled rates over extended periods. His pioneering research into biomedical compounds for drug delivery has impacts on a wide range of medical technologies, including anticancer therapy, vaccine development, gene therapy and more. 

Key Points: 
  • Dr. Robert Langer to Receive 2023 Dr. Paul Janssen Award for Groundbreaking Research in Biomedical Compounds for Drug Delivery
    NEW BRUNSWICK, N.J., Feb. 7, 2024 /PRNewswire/ -- Johnson & Johnson today announced Robert Langer, Sc.D., of Massachusetts Institute of Technology (MIT) as the winner of the 2023 Dr. Paul Janssen Award for Biomedical Research .
  • Dr. Langer was honored for his groundbreaking work in designing novel drug delivery systems that can deliver medications continuously, precisely, and at controlled rates over extended periods.
  • He joins 22 other scientists who have received the Dr. Paul Janssen Award since 2004, including eight who have gone on to win the Nobel Prize.
  • Johnson & Johnson will honor this remarkable scientist during a virtual symposium titled "Pioneering Novel Drug Delivery Systems" at the New York Academy of Sciences on February 8, 2024, from 9:00 a.m. to 12:30 p.m.

XCath CEO Eduardo Fonseca Highlights Potential for Telesurgery at Inaugural SRS Telesurgery Consensus Conference

Retrieved on: 
Wednesday, February 7, 2024

XCath , an early-stage medical device company dedicated to expanding endovascular treatment modalities through its robotic systems and guidewires, took part in a panel last week at the first-ever Telesurgery Consensus Conference hosted by the Society of Robotic Surgery (SRS).

Key Points: 
  • XCath , an early-stage medical device company dedicated to expanding endovascular treatment modalities through its robotic systems and guidewires, took part in a panel last week at the first-ever Telesurgery Consensus Conference hosted by the Society of Robotic Surgery (SRS).
  • XCath’s Chief Executive Officer, Eduardo Fonseca, participated in an industry panel titled, “Current clinical cases for telesurgery: If we had telesurgery today how would it change vascular emergency events.” Topics of discussion ranged from present telesurgery applications to treatment implications related to urgent vascular occurrences.
  • “The SRS Telesurgery Consensus Conference was the perfect forum for XCath to debut its innovative approach,” said Dr. Frederic H. Moll, Founder of Intuitive Surgical and Auris Health.
  • “Implementing modern technologies, like robotics, can improve both treatment precision and access to endovascular care, and I look forward to continue contributing to XCath’s advancements to the medical device landscape.”
    For more information about the SRS Telesurgery Consensus Conference, visit https://srobotics.org/ .

Arkuda Therapeutics Announces Option and Asset Purchase Agreement

Retrieved on: 
Wednesday, February 7, 2024

WATERTOWN, Mass., Feb. 7, 2024 /PRNewswire/ -- Arkuda Therapeutics, a biotechnology company applying novel insights at the intersection of lysosomal biology and neuronal health to develop medicines that change the trajectory of neurodegenerative disease such as Alzheimer's disease, Parkinson's disease and Frontotemporal dementia, today announced that it entered into an option and asset purchase agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, which grants Janssen an exclusive option to purchase Arkuda's portfolio of lysosomal function enhancers.

Key Points: 
  • WATERTOWN, Mass., Feb. 7, 2024 /PRNewswire/ -- Arkuda Therapeutics, a biotechnology company applying novel insights at the intersection of lysosomal biology and neuronal health to develop medicines that change the trajectory of neurodegenerative disease such as Alzheimer's disease, Parkinson's disease and Frontotemporal dementia, today announced that it entered into an option and asset purchase agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, which grants Janssen an exclusive option to purchase Arkuda's portfolio of lysosomal function enhancers.
  • Under the terms of the agreement, Arkuda will receive an upfront payment, consisting of an option payment from Janssen and an investment from Johnson & Johnson Innovation – JJDC, Inc. Janssen obtains the right to acquire Arkuda's portfolio of lysosomal function enhancers for an upfront payment and additional milestone payments.
  • "We're excited about the profile of ARKD-104 as a novel oral treatment for FTD-GRN, but also for other diseases driven by lysosomal dysfunction, and look forward to advancing ARKD-104 to the clinic in the coming year," said Gerhard Koenig, Ph.D., President and CEO.
  • "This agreement represents an important next step for Arkuda and provides validation of our leading-edge work in neurodegeneration."